Investing in Tomorrow's Health
NCL Investment Management invests transformational equity capital in entrepreneurs who have truly innovative technologies.
Our Investment Philosophy
The Modernisation of Healthcare will be one of the Greatest Growth Drivers of the 21st Century
NCL is a specialist healthcare investor. We create value by identifying companies who are at the forefront of transformational change. By applying the capital and human skills required to navigate this rapidly evolving sector, we prepare our companies to succeed both clinically and commercially.
Our focus is on the pioneers. Companies that are actively using innovation and technological advancement to help prevent, treat and cure a wide range of conditions.
Our mission is to address the challenges of our future health needs, whilst creating the next generation of valuable businesses.
NCLs Health Technology Fund II
NCL is currently investing from its Health Technology Fund II. The fund has been designed to take positions in pioneering new technologies that can create significant patient impact and produce upper quartile investment returns.
The fund has launched in partnership with several leading UK institutions including Kings College, NHS and our delivery partner Catalent Inc (NYSE: CLT). Documentation can be provided to professional investors only upon request.
Whether a potential investor or an entrepreneur we invite you to discuss your goals and ambitions with us.
Our team spans three generations and is vastly experienced in venture investment, fund structuring, entrepreneurship and business management. Our investment process is supported by expert scientific advisors
Research by emteq labs reveals how emotion measurement could redefine treatment for anxiety, depression and PTSD
The AI Journal has covered the latest research by portfolio Emteq, acknowledging their current success milestones and the implications of their research for emotion … Continued
LifeArc and UK government’s Future Fund provide £3.0m in funding to Centauri Subsidiary Avvinity Therapeutics
LifeArc, an independent medical research charity,announces a £3.0m co-investment in British biotech Avvinity Therapeutics alongside the UK government’s Future Fund. Lead investor LifeArc leveraged … Continued
Series B round led by Morningside Ventures provides foundation to accelerate the drug development of first-in-class immune-resetting therapies (London UK and Boston USA, 21 … Continued
Scalable, affordable, effective. Read about TC Biopharm’s stunning progress in the Financial Times here. “After winning approval from the UK’s Medicines and Healthcare Products … Continued